Fund moves
From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Aug 12, 2026 · Filed Aug 13, 2026
Chemours's See Remarks paid $30K out of pocket for Chemours shares. 6 other people at Chemours bought some too, in the same month.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$30,051
Shares × reported transaction price
$25K–$100K
+3.4%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
Not enough history to judge
Confirmed open-market purchases by the same insider in the available history
7 distinct insiders in 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
This purchase equals about 1.5% of the average reported total pay of the company's named executive officers other than the CEO, fiscal 2025 ($1.98M)
An average across the officers named in the pay versus performance table of the company's proxy statement (DEF 14A), filed 2026-03-10. This person may not be one of them, so it is not their own pay. A size comparison, not a judgement
8 days after results of Aug 4, 2026, 82 days before results of Nov 2, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $15.24 on Aug 12, 2026, 45% above its 52-week low and 45% below its high, after a 26% drop over the previous 30 trading days
52-week range $10.48 (Nov 20, 2025) to $27.94 (May 5, 2026), 27% of the way up, from 251 adjusted closes. 30 trading days earlier: $20.52 on Jun 30, 2026. Describes the past only, not a forecast
RSI 40, 15% under its 200-day average, 19% under its 50-day average, 45% below the 52-week high, 20-day volatility 94% a year, against the S&P 500: −21 points over 1 month, −43 points over 3 months, −32 points over 6 months
From the adjusted closes up to Aug 12, 2026. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
7 CC insiders bought within the same week; no week in filings since 2015 had that many buyers. Calderon Gerardo Familiar's first open-market purchase of CC in filings since 2015
Compared with every open-market purchase and sale of this company in SEC filings since 2006. A fact about the record, not a signal to trade
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +0.8% | −1.4% | +2.1% |
| 30 days | −8.0% | −2.0% | −6.0% |
| 90 days | −15.8% | −2.5% | −13.3% |
Past results only. Not a forecast.
Fund moves
From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Insider filing
Traded Aug 12 · filed 1 day later
Routine share withholding; mechanical by default.
Insider buying
6 insiders in a week, 2nd time since 2015Traded Aug 11 · filed 2 days later
The CEO of Chemours paid $51K out of pocket for Chemours shares. 6 other people at Chemours bought some too, in the same month.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.